[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"amr\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:amr":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100573312","phase-2-phase-2-study-of-alxn2030-in-patients-with-antibody-mediated-rejection-after-kidney-transplantation-100573312",false,"NCT06744647","Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation","A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of ALXN2030 in Adult Patients With Antibody-Mediated Rejection After Kidney Transplantation","CONCORD","Inclusion Criteria:\n\n* Kidney transplant received ≥ 6 months\n* Active or chronic active AMR according to Banff 2022 classification, based on Screening kidney biopsy\n* Either positive C4d on Screening kidney biopsy based on the Central Pathology Laboratory report and\u002For positive HLA Class I and\u002For II antigen-specific DSA as determined by the local laboratory's definition of positivity using single-antigen bead based assays\n* MVI score ≥ 2 (g ≥ 1 and ptc ≥ 1)\n* eGFR ≥ 30 mL\u002Fmin\u002F1.73 m2\n* Must be vaccinated against meningococcal infection from serogroups A, C, W, Y (and B where available) at least 14 days prior to but no more than 3 years prior to Day 1\n* Must be vaccinated for S pneumoniae prior to randomization\n* Must be vaccinated for H influenzae type B (where available) prior to randomization\n* Body weight ≥ 50 kg at Screening\n\nExclusion Criteria:\n\n* Biopsy-based diagnosis of any of the following at Screening:\n* TCMR, according to the Banff grade ≥ 1\n* Polyoma virus nephropathy\n* Severe thrombotic microangiopathy\n* Glomerulonephritis\n* ABO-incompatible transplant\n* uACR \\> 2200 mg\u002Fg\n* Multiorgan transplant recipient (except for previous multiple kidney transplants) or cell transplant (islet, bone marrow, stem cell) recipient\n* Planned or recent treatments, \\\u003C 90 days prior to the Screening Visit and during Screening, for Acute Rejection, AMR (including plasmapheresis, plasma exchange, IVIg, B-cell depleting therapy, IL inhibitors, proteasome inhibitors, high-dose corticosteroids \\[except for tapering\\]), HDS products with known hepatotoxic ingredients, TCMR (including T-cell depleting therapy), excluding the SoC immunosuppressant treatment which will be allowed and should be stable during the entire treatment.\n* Known medical or psychological condition, including substance abuse or use disorder (including alcohol), or risk factor that may interfere with study participation, pose additional risk, or confound study outcomes","ALL","18 Years","75 Years",{"count":21,"type":22},45,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","The primary objective of this study is to evaluate the efficacy of ALXN2030 compared with placebo on biopsy proven histologic resolution in participants with active or chronic active antibody-mediated rejection (AMR) at Week 52.",[28,29,30,31],"Antibody-Mediated Rejection","Kidney Transplantation","Biopsy-proven Histologic Scores","AMR",[33,28,29,34,31],"ALXN2030","Biopsy-proven histologic scores","RECRUITING","2026-06-17",{"date":38,"type":39},"2026-06-18","ACTUAL",{"date":41,"type":39},"2025-03-07",{"date":43,"type":22},"2028-11-07",{"name":45,"class":46},"Alexion Pharmaceuticals, Inc.","INDUSTRY",55,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":60,"conditions":61,"keywords":66,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":5},"100613083","crp-and-patient-information-leaflets-to-optimise-antibiotic-treatments-for-adults-with-respiratory-tract-infections-in-primary-care-in-kyrgyzstan-100613083","NCT07261969","CRP and Patient Information Leaflets to Optimise Antibiotic Treatments for Adults With Respiratory Tract Infections in Primary Care in Kyrgyzstan","2CARE INSTALL","Inclusion Criteria:\n\n* Adults aged 18 to 70 years with ARTI according to the attending HCW;\n* Having at least one of the following respiratory symptoms lasting for less than 2 weeks (with or without a fever):\n\n  * cough;\n  * shortness of breath;\n  * sore throat;\n  * stuffy nose;\n  * wheezing.\n* Able and willing to comply with all study requirements.\n* Able and willing to give informed consent.\n\nExclusion Criteria:\n\n* Severely ill and in need of urgent referral where measurement of POCT CRP is not relevant or would delay the process;\n* Terminally ill patients;\n* Patients with known immunosuppression or severe chronic disease (HIV, liver failure, kidney failure, history of neoplastic disease, long term systemic steroid use or similar conditions as assessed by the health worker or research team);\n* Patients who are not able to participate in follow-up procedures (lack of telephone etc.);\n* Have taken antibiotics within 24 hours before the index consultation;\n* Pregnant women;\n* Unable or unwilling to provide informed consent.","70 Years",{"count":57,"type":22},1050,[59],"NA","This study aims to determine how CRP levels and Patient Information Leaflets (PILs) affect antibiotic prescribing in adults with acute respiratory symptoms in Kyrgyz primary care. It will evaluate the effectiveness of PILs in reducing antibiotic use and ensuring safety and assess the effectiveness and safety of three CRP thresholds (20, 40, 60 mg\u002FL) for adults with acute respiratory tract infections. Conducted as a multicentre, open label, individually randomized controlled clinical trial with 21 days of blinded follow-up, the study will compare PIL to no PIL in a 1:1 ratio and assess antibiotic use and safety across the three CRP cut-offs in a 1:1:1 ratio, resulting in six groups. The trial will take place in 14 district primary healthcare centres in rural Kyrgyzstan and one urban primary healthcare centre in Bishkek.",[62,63,31,64,65],"Respiratory Tract Infection Bacterial","Respiratory Tract Infection Viral","CRP","Inflammation",[67,68,69,70,71,72,73],"CRP POCT","Primary care","ARVI","ARTI","Adults","PIL","RCT","2025-11-29",{"date":76,"type":39},"2025-12-03",{"date":78,"type":39},"2024-12-18",{"date":80,"type":22},"2027-04-30",{"name":82,"class":83},"Rigshospitalet, Denmark","OTHER"]